The shares of Teck Resources Limited (NYSE:TECK) has been pegged with a rating of Neutral by Citigroup in its latest research note that was published on April 22, 2020. Citigroup wasn’t the only research firm that published a report of Teck Resources Limited, with other equities research analysts also giving their opinion on the stock. The Benchmark Company advised investors in its research note published on March 02, 2020, to Buy the TECK stock while also putting a $14 price target. The stock had earned Neutral rating from BofA/Merrill Markets when it published its report on February 24, 2020. BMO Capital Markets was of a view that TECK is Market Perform in its latest report on November 21, 2019. BofA/Merrill thinks that TECK is worth Underperform rating.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 5 believe it has the potential for further growth, thus rating it as Hold while 13 advised investors to purchase the stock. The consensus currently stands at a Overweight while its average price target is $13.34. The price of the stock the last time has raised by 44.82% from its 52-Week high price while it is -65.80% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 51.55.
The shares of the company added by 13.59% during the trading session on Tuesday, reaching a low of $7.24 while ending the day at $8.11. During the trading session, a total of 13.56 million shares were traded which represents a -124.49% decline from the average session volume which is 6.04 million shares. TECK had ended its last session trading at $7.14. Teck Resources Limited debt-to-equity ratio currently stands at 0.31, while its quick ratio hovers at 0.60 TECK 52-week low price stands at $5.60 while its 52-week high price is $23.71.
The company in its last quarterly report recorded $0.13 earnings per share which is below the predicted by most analysts. The Teck Resources Limited generated 163.31 million in revenue during the last quarter. In the second quarter last year, the firm recorded $0.31 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -361.54%. Teck Resources Limited has the potential to record 1.08 EPS for the current fiscal year, according to equities analysts.
Investment analysts at BofA/Merrill published a research note on January 10, 2020 where it informed investors and clients that Aerie Pharmaceuticals Inc. (NASDAQ:AERI) is now rated as Neutral. Their price target on the stock stands at $27. SunTrust also rated AERI as Initiated on January 09, 2020, with its price target of $32 suggesting that AERI could surge by 59.99% from its current share price. Even though the stock has been trading at $14.74/share, analysts expect it to down by -5.22% to reach $34.92/share. It started the day trading at $15.01 and traded between $13.78 and $13.97 throughout the trading session.
A look at its technical shows that AERI’s 50-day SMA is 15.06 while its 200-day SMA stands at 20.00. The stock has a high of $44.13 for the year while the low is $10.80. The stock, however, witnessed a rise in its short on 04/15/20. Compared to previous close which recorded 9.25 M shorted shares, the short percentage went higher by 5.12%, as 9.72M TECK shares were shorted. At the moment, only 24.33% of Aerie Pharmaceuticals Inc. shares were sold short. The company’s average trading volume currently stands at 967.23K shares, which means that the short-interest ratio is just 10.05 days. Over the past seven days, the company moved, with its shift of 1.01%. Looking further, the stock has dropped -35.11% over the past 90 days while it lost -34.47% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Wellington Management Co. LLP sold more AERI shares, decreasing its portfolio by -2.06% during the last quarter. This move now sees The Wellington Management Co. LLP selling -131,244 shares in the last quarter, thus it now holds 6,241,041 shares of AERI, with a total valuation of $84,254,054. The Vanguard Group, Inc. meanwhile bought more AERI shares in the recently filed quarter, changing its stake to $56,010,164 worth of shares.
Similarly, BlackRock Fund Advisors decreased its Aerie Pharmaceuticals Inc. shares by 1.17% during the recently filed quarter. After selling 3,168,421 shares in the last quarter, the firm now controls -37,529 shares of Aerie Pharmaceuticals Inc. which are valued at $42,773,684. In the same vein, Deerfield Management Company LP decreased its Aerie Pharmaceuticals Inc. shares by during the most recent reported quarter. The firm bought 759,892 shares during the quarter which decreased its stakes to 2,532,147 shares and is now valued at $34,183,985. Following these latest developments, around 2.00% of Aerie Pharmaceuticals Inc. stocks are owned by institutional investors and hedge funds.